Galectin Therapeutics (GALT) Competitors

Galectin Therapeutics (NASDAQ:GALT) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Does the MarketBeat Community believe in GALT or PHAT?

Galectin Therapeutics received 256 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. However, 72.80% of users gave Phathom Pharmaceuticals an outperform vote while only 59.11% of users gave Galectin Therapeutics an outperform vote.

Company	Underperform	Outperform
Galectin Therapeutics	Outperform Votes 347 59.11%	Underperform Votes 240 40.89%
Phathom Pharmaceuticals	Outperform Votes 91 72.80%	Underperform Votes 34 27.20%

Do institutionals & insiders believe in GALT or PHAT?

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by company insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend GALT or PHAT?

Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 638.26%. Phathom Pharmaceuticals has a consensus target price of $23.00, suggesting a potential upside of 341.46%. Given Galectin Therapeutics' higher probable upside, equities research analysts plainly believe Galectin Therapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phathom Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has higher valuation and earnings, GALT or PHAT?

Galectin Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$41.07M	-$0.73	-2.04
Phathom Pharmaceuticals	$26.27M	13.56	-$201.59M	-$5.69	-0.92

Is GALT or PHAT more profitable?

Galectin Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-163.15%
Phathom Pharmaceuticals	-1,292.14%	N/A	-79.57%

Which has more volatility and risk, GALT or PHAT?

Galectin Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Does the media refer more to GALT or PHAT?

In the previous week, Phathom Pharmaceuticals had 4 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Phathom Pharmaceuticals and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 1.89 beat Phathom Pharmaceuticals' score of 0.56 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Galectin Therapeutics	Very Positive
Phathom Pharmaceuticals	Positive

Summary

Phathom Pharmaceuticals beats Galectin Therapeutics on 9 of the 17 factors compared between the two stocks.